Clinical trials: Chronic Disease
Knee Osteoarthritis, Knee Arthritis
Performance of MOTO Medial® Unicompartmental Knee Arthroplasty
This is a prospective, multi-center study, designed to assess mid-term performance of the MOTO Medial® Unicompartmental Knee Arthroplasty (UKA), with patient report outcomes, clinical findings and radiographic analysis.
- Conditions
- Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic
- Trial name
- NCT03211663
- Testing
- MOTO Medial® UKA
- Where
- 5 sites in United States
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Medacta USA
Chronic Inflammatory Demyelinating Polyneuropathy
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with…
- Trial name
- pHeNIx (NCT04672733)
- Testing
- Hizentra
- Where
- 27 sites in France
- Volunteers
- 100 people
- Sponsor
- CSL Behring
Secondary Hyperparathyroidism
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National…
- Trial name
- NCT00135304
- Testing
- Sensipar®, Vitamin D
- Volunteers
- 170 people
- Sponsor
- Amgen
Parkinson's Disease (PD)
Observational Study Evaluating Robotic Spinal Mobilization in 16 Parkinson's Disease Participants. The Study Recorded Changes in Mobility, Sit-to-stand Performance, and Pain Scores After a 2-week Intervention With the BackHug Device.
The goal of this completed observational pilot study was to evaluate the immediate and short-term clinical effects of robotic spinal mobilization on motor and non-motor symptoms in community-dwelling adults with Parkinson's…
- Trial name
- NCT07384364
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Pacla Medical Limited
Heart Failure
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin…
- Trial name
- PRIORITIZE HF (NCT03532009)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Coronary Artery Chronic Total Occlusion
Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)
Prospective, non-randomized, multicenter study in subjects with coronary artery chronic total occlusions (CTOs). Published results of safety and effectiveness of conventional techniques will be used for comparison.
- Trial name
- FAST-CTOs (NCT00886899)
- Testing
- Recanalization of a coronary chronic total occlusion
- Where
- 16 sites in United States
- Volunteers
- 147 people
- Sponsor
- BridgePoint Medical
Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
This study will be conducted to evaluate the safety and tolerability of ferric citrate in pediatric participants with iron deficiency anemia (IDA) associated with non-dialysis dependent chronic kidney disease (NDD-CKD).
- Trial name
- NCT04649411
- Testing
- ferric citrate, standard of care
- Sponsor
- Keryx Biopharmaceuticals
Corneal Edema
EndoArt® Implantation in Subjects With Chronic Corneal Edema
The EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema.The EndoArt® (Artificial Endothelial layer) is a permanent implant, constructed of a clear, transparent, foldable…
- Trial name
- NCT05139771
- Testing
- THE ENDOART® IMPLANTATION (Artificial Endothelial layer)
- Where
- 12 sites in France, Georgia and 4 more
- Volunteers
- 52 people
- Sponsor
- Eye-yon Medical
End Stage Renal Disease (ESRD), Kidney Failure
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
The goal of the CSP-2002 clinical trial is to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD).
- Conditions
- End Stage Renal Disease (ESRD), Kidney Failure, Chronic Renal Disease, Hemodialysis
- Trial name
- NCT04671771
- Testing
- InnAVasc Arteriovenous Graft (IG) surgical implant
- Where
- 22 sites in United States
- Volunteers
- 133 people
- Sponsor
- W.L.Gore & Associates
Chronic Hepatitis B
Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
The purpose of the study is to investigate the long-term safety and the antiviral activity of the optimal doses of LB80380 for additional 48 weeks in treatment-naive patients with chronic hepatitis B infection compared to…
- Trial name
- LB80380 (NCT01242787)
- Testing
- LB80380, Entecavir 0.5 mg
- Where
- 2 sites in China, South Korea
- Volunteers
- 115 people
- Sponsor
- LG Life Sciences
Chronic Obstructive Pulmonary Disease
A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease
This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic…
- Trial name
- NCT07633314
- Testing
- TQC3927 inhalation aerosol, Glyceryl bromide/formoterol inhalation aerosol
- Where
- 16 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Long COVID
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID.
- Trial name
- IMPACT-LC (NCT06974084)
- Testing
- Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- HealthBio, Inc.
Hepatitis B, Chronic
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
This is a multi centre, two parallel arm, randomized, open-label, Phase 2a experimental study of oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect when administered to non-treated…
- Trial name
- NCT04365933
- Testing
- EYP001a, Entecavir, Pegylated interferon alpha2a
- Where
- 6 sites in Hong Kong, South Korea and 1 more
- Volunteers
- 20 people
- Sponsor
- Enyo Pharma
Heart Failure
Model 4195 Left Ventricular (LV) Lead Chronic Performance Study
Evaluate long-term performance of the 4195 LV Lead. This evaluation is based on the number of lead-related complications occuring during the study compared to the number of leads enrolled in the study.
- Trial name
- NCT00869921
- Where
- 67 sites in United States, Canada and 1 more
- Volunteers
- 1,322 people
- Sponsor
- Medtronic
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
The main objective of the current trial is to investigate safety, tolerability, pharmacokinetics and effect on inflammation of oral BI 1026706 administered twice daily for 4 weeks in patients with COPD.
- Trial name
- NCT02642614
- Testing
- BI 1026706
- Where
- 10 sites in Denmark, Germany and 2 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
cGvHD
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.
- Trial name
- NCT06186804
- Testing
- ABSK021
- Where
- 14 sites in China
- Volunteers
- 64 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Multiple Sclerosis, Secondary Progressive
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive…
- Trial name
- INSPIRE (NCT02430532)
- Testing
- dimethyl fumarate
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 58 people
- Sponsor
- Biogen
Constipation
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).
- Trial name
- NCT00529087
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 78 sites in United States
- Volunteers
- 460 people
- Sponsor
- Bausch Health Americas, Inc.
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and hydroxyurea, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00083187
- Testing
- hydroxyurea, laromustine
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 230 people
- Sponsor
- Vion Pharmaceuticals
Refractory Chronic Cough
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- CALM-2 (NCT07650084)
- Testing
- BLU-5937
- Where
- 38 sites in China
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.